Patients with chronic hepatitis B under nucleos(t)ide analog therapy with Omicron BA.5 infection: A retrospective study in South China
No significant exacerbation of COVID-19 symptoms was observed in conjunction with the efficacy of COVID-19 booster vaccinations. There were no notable alterations in liver functions except for GLB. HBV reactivation, as evidenced by increased HBV DNA, was observed among patients with CHB after Omicron BA.5 infection. These changes were not affected by ETV versus TFV administration; however, TFV resulted in a significant increase in SARS-CoV-2 antibody levels. Further studies are required to improve care and therapeutics for patients with CHB who contracted COVID-19.
Authors
- Zhishuo Mo (ORCID: https://orcid.org/0000-0002-3756-8578)
- Dabiao Chen (ORCID: https://orcid.org/0000-0002-2984-9695)
- Junjian Chen (ORCID: https://orcid.org/0009-0005-4073-8397)
- P G Wang (ORCID: https://orcid.org/0000-0002-5397-5579)
- Ziying Lei (ORCID: https://orcid.org/0000-0003-3071-0698)
- Ying Zhang
Institutions
- Sun Yat-sen University (CN)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
Publication Details
- Journal
- Liver Research
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1016/j.livres.2024.11.003
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00